Interestingly, FCGBP was upregulated in various tumors (e.g., cholangiocarcinoma, glioblastoma multiforme, and HCC), but downregulated in some tumors, such as head and neck squamous cell carcinoma, kidney chromophobe carcinoma, kidney renal clear cell carcinoma, etc. Meanwhile, we analyzed the FCGBP expression levels in different cancer types using the data from the TIMER database, which were similar to the above data (Figure S5c). Here, FCGBP is linked to chromophobe renal cell carcinoma.